Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Alterity Therapeutics Limited

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

HIGHLIGHTS GRANTED U.S. FDA FAST TRACK DESIGNATION FOR ATH434 TO TREAT MULTIPLE SYSTEM ATROPHY (MSA) REPORTED POSITIVE TOPLINE DATA FROM OPEN-LABEL PHASE 2 CLINICAL TRIAL OF ATH434 IN MSA PRESENTED ADDITIONAL ANALYSES FROM THE ATH434-201 TRIAL DEMONSTRATING CONTINUED ROBUST EFFICACY FOR THE TREATMENT OF MSA CASH BALANCE ON 30 JUNE 2025 OF A$40.66M MELBOURNE, AUSTRALIAAND SAN FRANCISCO, JULY 30, 2025 (GLOBE NEWSWIRE) -- ALTERITY THERAPEUTICS (ASX: ATH, NASDAQ: ATHE) (ALTERITY OR THE COMPANY), A BIOTECHNOLOGY COMPANY DEDICATED TO DEVELOPING DISEASE MODIFYING TREATMENTS FOR NEURODEGENERATIVE DISEASES, TODAY RELEASED ITS APPENDIX 4C QUARTERLY CASH FLOW REPORT AND UPDATE ON COMPANY ACTIVITIES FOR THE QUARTER ENDING 30 JUNE 2025 (Q4 FY25). U.S. FDA FAST TRACK DESIGNATION FOR ATH434 IN MSA WAS THE HIGHLIGHT OF THE RECENT QUARTER THAT ALSO FEATURED ADDITIONAL POSITIVE CLINICAL DATA FROM OUR PHASE 2 DOUBLE-BLIND TRIAL, SAID DAVID STAMLER, M.D.

APPENDIX 4C  Q4 FY25 QUARTERLY CASH FLOW REPORT

 ATH434 DEMONSTRATED CLINICAL BENEFIT ON THE UNIFIED MSA RATING SCALE AND GLOBAL MEASURES OF NEUROLOGICAL SYMPTOMS 

ALTERITY THERAPEUTICS REPORTS POSITIVE TOPLINE DATA FROM OPEN-LABEL PHASE 2 CLINICAL TRIAL OF ATH434 IN MULTIPLE SYSTEM ATROPHY

 PEER-REVIEWED PUBLICATION IN ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY HIGHLIGHTS THE USE OF THE MSA ATROPHY INDEX DEVELOPED TO DIAGNOSE AND TRACK DISEASE PROGRESSION IN MULTIPLE SYSTEM ATROPHY 

ALTERITY THERAPEUTICS ANNOUNCES PUBLICATION ON NOVEL MRI ENDPOINT FROM THE BIOMUSE NATURAL HISTORY STUDY

MELBOURNE, AUSTRALIA AND SAN FRANCISCO, JUNE 23, 2025 (GLOBE NEWSWIRE) -- ALTERITY THERAPEUTICS (ASX: ATH, NASDAQ: ATHE) (ALTERITY OR THE COMPANY), A BIOTECHNOLOGY COMPANY DEDICATED TO DEVELOPING DISEASE MODIFYING TREATMENTS FOR NEURODEGENERATIVE DISEASES, TODAY ANNOUNCEDTHAT DAVID STAMLER, M.D., CHIEF EXECUTIVE OFFICER OF ALTERITY, WILL PARTICIPATE IN A FIRESIDE CHAT HOSTED BY MST ACCESS ON WEDNESDAY, 25 JUNE 2025 IN AUSTRALIA / TUESDAY, 24 JUNE 2025 IN THE UNITED STATES. DR. STAMLER WILL PROVIDE A CORPORATE UPDATE WITH A FOCUS ON THE PROGRESS MADE ON THE ATH434 DEVELOPMENT PROGRAM IN MULTIPLE SYSTEM ATROPHY SINCE THE COMPANY RELEASED POSITIVE PHASE 2 DATA IN JANUARY.

ALTERITY THERAPEUTICS TO PROVIDE CORPORATE UPDATE IN FIRESIDE CHAT

 ATH434 PHASE 2 DATA DEMONSTRATED CLINICALLY MEANINGFUL EFFICACY ON MULTIPLE CLINICAL ENDPOINTS   MSA ATROPHY INDEX (MSAAI) ENHANCES MSA DIAGNOSIS AND MONITORING   BIOMUSE STUDY SHOWS HIGHER - SYNUCLEIN CONCENTRATION IS ASSOCIATED WITH GREATER BURDEN OF ORTHOSTATIC SYMPTOMS  MELBOURNE, AUSTRALIA AND SAN FRANCISCO, MAY 12, 2025 (GLOBE NEWSWIRE) -- ALTERITY THERAPEUTICS (ASX: ATH, NASDAQ: ATHE) (ALTERITY OR THE COMPANY), A BIOTECHNOLOGY COMPANY DEDICATED TO DEVELOPING DISEASE MODIFYING TREATMENTS FOR NEURODEGENERATIVE DISEASES, TODAY ANNOUNCED THAT SEVERAL ORAL AND POSTER PRESENTATIONS RELATED TO ALTERITY'S CLINICAL PROGRAMS IN MULTIPLE SYSTEM ATROPHY (MSA) WERE FEATURED AT THE 2025 INTERNATIONAL MSA CONGRESS. THE CONGRESS WAS PRESENTED BY MISSION MSA, A NON-PROFIT ORGANIZATION DEDICATED TO IMPROVING THE QUALITY OF LIFE AND BUILDING HOPE FOR PEOPLE AFFECTED BY MSA THROUGH SUPPORT SERVICES, EDUCATIONAL RESOURCES, RESEARCH FUNDING, AND COMMUNITY ENGAGEMENT.

ALTERITY THERAPEUTICS PROMINENTLY FEATURED AT THE INTERNATIONAL MSA CONGRESS

MELBOURNE, AUSTRALIA AND SAN FRANCISCO, MAY 07, 2025 (GLOBE NEWSWIRE) -- ALTERITY THERAPEUTICS (ASX: ATH, NASDAQ: ATHE) (ALTERITY OR THE COMPANY), A BIOTECHNOLOGY COMPANY DEDICATED TO DEVELOPING DISEASE MODIFYING TREATMENTS FOR NEURODEGENERATIVE DISEASES, TODAY ANNOUNCED THAT MULTIPLE ORAL AND POSTER PRESENTATIONS RELATED TO ALTERITY'S CLINICAL PROGRAMS IN MULTIPLE SYSTEM ATROPHY (MSA) WILL BE FEATURED AT THE 2025 INTERNATIONAL MSA CONGRESS TAKING PLACE MAY 9 - 11, 2025 IN BOSTON, MA, USA. THE CONGRESS IS PRESENTED BY MISSION MSA, A NON-PROFIT ORGANIZATION DEDICATED TO IMPROVING THE QUALITY OF LIFE AND BUILDING HOPE FOR PEOPLE AFFECTED BY MSA THROUGH SUPPORT SERVICES, EDUCATIONAL RESOURCES, RESEARCH FUNDING, AND COMMUNITY ENGAGEMENT.

ALTERITY THERAPEUTICS ANNOUNCES MULTIPLE ORAL AND POSTER PRESENTATIONS TO BE FEATURED AT THE INTERNATIONAL MSA CONGRESS

 FAST TRACK DESIGNATION HIGHLIGHTS POTENTIAL OF ATH434 TO ADDRESS HIGH UNMET NEED FOR INDIVIDUALS WITH MSA  MELBOURNE, AUSTRALIA AND SAN FRANCISCO, MAY 05, 2025 (GLOBE NEWSWIRE) -- ALTERITY THERAPEUTICS (ASX: ATH, NASDAQ: ATHE) (ALTERITY OR THE COMPANY), A BIOTECHNOLOGY COMPANY DEDICATED TO DEVELOPING DISEASE MODIFYING TREATMENTS FOR NEURODEGENERATIVE DISEASES, TODAY ANNOUNCEDTHAT THE U.S. FOOD AND DRUG ADMINISTRATION(FDA) HAS GRANTED FAST TRACK DESIGNATION FOR ATH434 FOR THE TREATMENT OF MULTIPLE SYSTEM ATROPHY (MSA). THIS DESIGNATION IS INTENDED TO ACCELERATE THE DEVELOPMENT AND REVIEW OF NOVEL INVESTIGATIONAL PRODUCTS SUCH AS ATH434 AND RECOGNIZES ITS POTENTIAL AS AN INNOVATIVE APPROACH TO ADDRESS THE HIGH UNMET NEED FOR TREATING MSA, A DISEASE WITH NO APPROVED THERAPY.

ALTERITY THERAPEUTICS GRANTED U.S. FDA FAST TRACK DESIGNATION FOR ATH434 TO TREAT MULTIPLE SYSTEM ATROPHY

HIGHLIGHTS REPORTED POSITIVE TOPLINE DATA FOR ATH434-201 RANDOMIZED, DOUBLE-BLIND PHASE 2 CLINICAL TRIAL IN MULTIPLE SYSTEM ATROPHY (MSA) LED BY ROBUST CLINICAL EFFICACY PHASE 2 DATA FEATURED IN AN ORAL PRESENTATION AT THE AMERICAN ACADEMY OF NEUROLOGY ANNUAL MEETING ATH434-202 OPEN-LABEL TRIAL IN ADVANCED MSA COMPLETED IN MARCH 2025 CASH BALANCE ON 31 MARCH 2025 OF A$17.96M WITH AN ADDITIONAL A$27.1M RAISED SUBSEQUENT TO THE END OF THE QUARTER MELBOURNE, AUSTRALIA AND SAN FRANCISCO, APRIL 30, 2025 (GLOBE NEWSWIRE) -- ALTERITY THERAPEUTICS (ASX: ATH, NASDAQ: ATHE) (ALTERITY OR THE COMPANY), A BIOTECHNOLOGY COMPANY DEDICATED TO DEVELOPING DISEASE MODIFYING TREATMENTS FOR NEURODEGENERATIVE DISEASES, TODAY RELEASED ITS APPENDIX 4C QUARTERLY CASH FLOW REPORT AND UPDATE ON COMPANY ACTIVITIES FOR THE QUARTER ENDING 31 MARCH 2025 (Q3 FY25). DAVID STAMLER, M.D.

APPENDIX 4C  Q3 FY25 QUARTERLY CASH FLOW REPORT

MELBOURNE, AUSTRALIA AND SAN FRANCISCO, APRIL 28, 2025 (GLOBE NEWSWIRE) -- ALTERITY THERAPEUTICS (ASX: ATH, NASDAQ: ATHE) (ALTERITY OR THE COMPANY), A BIOTECHNOLOGY COMPANY DEDICATED TO DEVELOPING DISEASE MODIFYING TREATMENTS FOR NEURODEGENERATIVE DISEASES, TODAY ANNOUNCED THAT DAVID STAMLER, M.D., CHIEF EXECUTIVE OFFICER PRESENTED THE ATH434-201 PHASE 2 CLINICAL TRIAL RESULTS AT THE ANNUAL MSA RESEARCH SYMPOSIUM HOSTED BY UNIVERSITY COLLEGE LONDON, INSTITUTE OF NEUROLOGY IN PARTNERSHIP WITH THE MSA TRUST OF THE U.K.

ALTERITY THERAPEUTICS PRESENTS ATH434-201 PHASE 2 CLINICAL TRIAL RESULTS AT EUROPEAN MSA SYMPOSIUM

 CLINICALLY MEANINGFUL EFFICACY OBSERVED ON MULTIPLE ASSESSMENTS   CONFIRMED TARGET ENGAGEMENT WITH REDUCED IRON SIGNAL IN MSA AFFECTED BRAIN REGIONS  MELBOURNE, AUSTRALIA AND SAN FRANCISCO, APRIL 10, 2025 (GLOBE NEWSWIRE) -- ALTERITY THERAPEUTICS (ASX: ATH, NASDAQ: ATHE) (ALTERITY OR THE COMPANY), A BIOTECHNOLOGY COMPANY DEDICATED TO DEVELOPING DISEASE MODIFYING TREATMENTS FOR NEURODEGENERATIVE DISEASES, TODAY ANNOUNCED THAT NEW PRESENTATIONS RELATED TO ITS MULTIPLE SYSTEM ATROPHY (MSA) PROGRAM WERE DELIVERED AT THE AMERICAN ACADEMY OF NEUROLOGY (AAN) 2025 ANNUAL MEETING, ONE OF THE PREMIER GLOBAL NEUROLOGY MEETINGS. NOTABLY, NEW DATA FROM THE ATH434-201 TRIAL WAS PROMINENTLY FEATURED VIA AN ORAL PRESENTATION DURING A SCIENTIFIC PLATFORM SESSION ON MOVEMENT DISORDERS.

ALTERITY THERAPEUTICS PRESENTS ENCOURAGING NEW DATA FROM ITS ATH434 PHASE 2 TRIAL IN MULTIPLE SYSTEM ATROPHY AT THE AMERICAN ACADEMY OF NEUROLOGY ANNUAL MEETING

Alterity Therapeutics Limited

ATHE

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Alterity Therapeutics Limited

ATHE.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ATHE